- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Polypoidal choroidal vasculopathy.
Displaying page 1 of 1.
EudraCT Number: 2013-004464-54 | Sponsor Protocol Number: BAY86-5321/16995 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic ... | |||||||||||||
Medical condition: Polypoidal Choroidal Vasculopathy (PCV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002384-15 | Sponsor Protocol Number: 3.0 | Start Date*: 2014-10-23 | ||||||||||||||||||||||||||
Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie | ||||||||||||||||||||||||||||
Full Title: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV | ||||||||||||||||||||||||||||
Medical condition: Exsudative Maculopathies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001368-20 | Sponsor Protocol Number: ECR-AMD-2015-09 | Start Date*: 2015-09-01 | |||||||||||
Sponsor Name:AIBILI - Association for Innovation and Biomedical Research ob Light and Image | |||||||||||||
Full Title: A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic The... | |||||||||||||
Medical condition: Polypoidal Choroidal Vasculopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004917-10 | Sponsor Protocol Number: TIGER | Start Date*: 2023-06-29 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro... | |||||||||||||
Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000690-73 | Sponsor Protocol Number: BAY86-5321/21912 | Start Date*: 2023-06-06 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi... | |||||||||||||
Medical condition: Neovascular (wet) age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004825-34 | Sponsor Protocol Number: KHB-1801 | Start Date*: 2019-01-14 | |||||||||||
Sponsor Name:Chengdu Kanghong Biotechnology Co., Ltd. | |||||||||||||
Full Title: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration | |||||||||||||
Medical condition: Neovascular Age Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) LT (Prematurely Ended) AT (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003132-39 | Sponsor Protocol Number: BAY86-5321/17508 | Start Date*: 2016-03-17 |
Sponsor Name:Bayer AG | ||
Full Title: Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled,... | ||
Medical condition: Neovascular age-related macular degeneration (nAMD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005556-25 | Sponsor Protocol Number: OFT-ETAMSILATO-4.2.2 | Start Date*: 2015-05-11 |
Sponsor Name:Investigacion Independiente | ||
Full Title: Open extension study for patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulatedcontrolled treatment to evaluate safety and efficacy o... | ||
Medical condition: Aged related macula degeneration (ARMD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004826-14 | Sponsor Protocol Number: KHB-1802 | Start Date*: 2019-01-09 | |||||||||||
Sponsor Name:Chengdu Kanghong Biotechnology Co., Ltd. | |||||||||||||
Full Title: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration | |||||||||||||
Medical condition: Neovascular Age Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) SK (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003226-71 | Sponsor Protocol Number: MR42410 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & ... | |||||||||||||
Medical condition: Neovascular Age-Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FI (Completed) HU (Completed) DK (Completed) PT (Completed) GR (Completed) IE (Completed) NL (Completed) DE (Completed) AT (Completed) PL (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
